(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 23.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.1%.
Adma Biologics's revenue in 2026 is $510,173,000.On average, 6 Wall Street analysts forecast ADMA's revenue for 2026 to be $153,615,050,112, with the lowest ADMA revenue forecast at $145,196,123,240, and the highest ADMA revenue forecast at $160,042,966,272. On average, 6 Wall Street analysts forecast ADMA's revenue for 2027 to be $187,674,193,872, with the lowest ADMA revenue forecast at $177,566,718,442, and the highest ADMA revenue forecast at $195,402,459,133.
In 2028, ADMA is forecast to generate $227,149,077,294 in revenue, with the lowest revenue forecast at $213,674,031,115 and the highest revenue forecast at $236,563,509,521.